Nephros Products:
The US ESRD treatment industry is experiencing an economic upheaval; this manifests itself in the movement toward global capitation and reimbursement based on clinical performance, combined with fixed reimbursement structures and rising costs. Nephros is working to provide the critical answers to these issues by creating products that:

• Create exceptional operational efficiencies for the clinic,
• Reduce the required drug regimen accompanying dialysis by offering superior therapy,
• Offer new marketing attributes to attract patients, and
• Address the unique and specific needs of each segment of the global marketplace.

Hemodiafiltration has made a significant positive impact on the ESRD patients who have been treated with it. Research has shown that a host of physiological maladies common to the patients on conventional hemodialysis do not manifest in hemodiafiltration patients. Patients on HDF live longer, have fewer problems associated with ß₂ microglobulin and require fewer medications than their conventional hemodialysis counterparts.

Patients, physicians and caregivers all agree that hemodiafiltration is the superior modality for the ESRD patient. It is predicted that HDF will continue to be the fastest growing modality in ESRD care during the next decade. Nephros research and Nephros products address this growing segment of the ESRD market. Our engineering and design lead the industry in innovation and efficacy.

All site contents ©2003, Nephros, Inc.